← Human Trials & Peer-Reviewed Studies
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Plain-language guide to PMID 18160462 (2008): open-label randomized controlled trial study of Teriparatide in 245 women, osteoporosis and bone density.
Key Facts
- PMID
- 18160462
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Boonen S et al. (11 authors)
- DOI
- 10.1210/jc.2007-0711
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Teriparatide in the context of osteoporosis and bone density.
Why It Was Studied
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Who Took Part
The study group was 245 women.
The age groups tagged for this paper are middle-aged adults and older adults, women only.
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
How the Study Was Run
In design terms this was a randomized and open-label study.
The women were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
Nothing was hidden in this open-label Teriparatide study: the women and staff both knew the treatment.
Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months.
What Was Measured
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
The subject headings attached to it are Bone Density, Bone Density Conservation Agents, Bone Resorption, Osteogenesis, Osteoporosis, Postmenopausal, Peptide Fragments and Procollagen.
What This Means in Plain Language
The paper is a randomized and open-label study of Teriparatide in 245 women in people with osteoporosis and bone density.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.